Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Marinus Pharma CS (NQ: MRNS )

12.60 USD -0.13 (-1.02%)
Official Closing Price Updated: 7:43 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Marinus Pharma CS

< Previous 1 2 3 4 5 6 Next >
Research Uncovers New Role Psychedelics Could Play in Therapy
FinancialBuzz.com News Commentary 
From PR Newswire
Marinus Pharmaceuticals to Host Pipeline Update Webinar
From GlobeNewswire News Releases
Marinus Pharmaceuticals to Present at SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum
From GlobeNewswire News Releases
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Marinus Pharmaceuticals Appoints Martha Manning as Vice President, General Counsel and Secretary
From GlobeNewswire News Releases
Marinus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From GlobeNewswire News Releases
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
From GlobeNewswire News Releases
Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock
From GlobeNewswire News Releases
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results
From GlobeNewswire News Releases
Marinus Pharmaceuticals Announces Formation of Scientific Advisory Board
Board includes 6 globally recognized seizure disorder experts 
From GlobeNewswire News Releases
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Marinus Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 4, 2020
From GlobeNewswire News Releases
Benitec Biopharma Appoints Edward Smith to the Board of Directors
Benitec Biopharma, Inc., a successor entity to Benitec Biopharma Limited (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today announced... 
From PR Newswire
MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
From GlobeNewswire News Releases
Marinus Pharmaceuticals Appoints Sasha Damouni Ellis as Vice President, Investor Relations and Corporate Communications
From GlobeNewswire News Releases
Marinus Pharmaceuticals Provides Business Reports Update and 2019 Financial Results
From GlobeNewswire News Releases
Marinus Pharmaceuticals Completes Targeted Enrollment in Pivotal Phase 3 Study for CDKL5 Deficiency Disorder
Top-line data on-track for Q3 2020 
From GlobeNewswire News Releases
Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences
From GlobeNewswire News Releases
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Marinus Pharmaceuticals to Present Ganaxolone EEG Clinical Data in Status Epilepticus at the American Clinical Neurophysiology Society 2020 Annual Meeting
From GlobeNewswire News Releases
Marinus Provides Business Outlook for 2020
From GlobeNewswire News Releases
Marinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare Conference
From GlobeNewswire News Releases
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Marinus Pharmaceuticals Announces Closing of $70 Million Public Offering of Common Stock and Concurrent Private Placement Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From GlobeNewswire News Releases
Marinus Pharmaceuticals Appoints Elan Ezickson to Board of Directors
From GlobeNewswire News Releases
Corrected Press Release: Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement
From GlobeNewswire News Releases
Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement
From GlobeNewswire News Releases
Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
From GlobeNewswire News Releases
Marinus Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in Tuberous Sclerosis Complex
From GlobeNewswire News Releases
Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.